Erin Colgan
Treasurer chez Massachusetts Biotechnology Education Foundation
Fortune : 70 835 $ au 31/03/2024
Profil
Erin Colgan is currently the Treasurer at the Massachusetts Biotechnology Education Foundation.
Previously, Ms. Colgan held the position of Senior Director-Global Revenue at Vertex Pharmaceuticals, Inc. from 2010 to 2019.
Ms. Colgan then served as the Vice President-Commercial Planning at Intarcia Therapeutics, Inc. from 2019 to 2020.
Currently, Ms. Colgan is also the Chief Financial Officer at Sensei Biotherapeutics, Inc. starting from 2022.
Ms. Colgan obtained an undergraduate degree from the University of Massachusetts.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/02/2024 | 67 462 ( 0,27% ) | 70 835 $ | 31/03/2024 |
Postes actifs de Erin Colgan
| Sociétés | Poste | Début |
|---|---|---|
Massachusetts Biotechnology Education Foundation
 Massachusetts Biotechnology Education Foundation Miscellaneous Commercial ServicesCommercial Services Massachusetts Biotechnology Education Foundation supports science and biotechnology education in Massachusetts through school programs and workforce training. The company was founded in 2001 and is headquartered in Cambridge, MA. | Treasurer | - |
Anciens postes connus de Erin Colgan
| Sociétés | Poste | Fin |
|---|---|---|
| SENSEI BIOTHERAPEUTICS, INC. | Director of Finance/CFO | 10/04/2024 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01/06/2020 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01/08/2019 |
Formation de Erin Colgan
| University of Massachusetts | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| SENSEI BIOTHERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
Massachusetts Biotechnology Education Foundation
Massachusetts Biotechnology Education Foundation Miscellaneous Commercial ServicesCommercial Services Massachusetts Biotechnology Education Foundation supports science and biotechnology education in Massachusetts through school programs and workforce training. The company was founded in 2001 and is headquartered in Cambridge, MA. | Commercial Services |
